alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Home › Research › Topics › plasma-ptau217

plasma-ptau217

4 studies tagged plasma-ptau217, dated 2024-01-05 to 2025-08-06. Bibliography: BibTeX (.bib) · RIS (.ris)

Newest in this topic

  1. Potential utility of plasma pTau217 for assessing amyloid and tau biomarker profiles 2025-08-06
  2. Plasma pTau217 ratio predicts continuous regional brain tau accumulation in amyloid-positive early Alzheimer's disease 2024-11-22
  3. Plasma pTau217 predicts continuous brain amyloid levels in preclinical and early Alzheimer's disease 2024-06-28

Studies

4 studies carry this tag.

Date range

2024 to 2025

Top journals

  • Alzheimer's & dementia : the journal of the Alzheimer's Association 2
  • European journal of nuclear medicine and molecular imaging 1
  • Scientific reports 1

Newest first, then by address. Each study has a usefulness score out of 100 (rubric version 4.0); tap a score to see what makes it up. Tags were assigned automatically from each study's title and summary. The same studies as a filter in the library.

  1. Potential utility of plasma pTau217 for assessing amyloid and tau biomarker profiles

    ✓ Peer-reviewed alzhub usefulness score 76 out of 100. European journal of nuclear medicine and molecular imaging 2025-08-06 Biomarkers

    Plasma pTau217 is effective for predicting A/T biomarker profile and cognitive decline, though further study is needed to better explain its association with Aβ and tau PET staging.

  2. Plasma pTau217 ratio predicts continuous regional brain tau accumulation in amyloid-positive early Alzheimer's disease

    ✓ Peer-reviewed alzhub usefulness score 74 out of 100. Alzheimer's & dementia : the journal of the Alzheimer's Association 2024-11-22 Biomarkers

    PTau217R reliably predicts regional tau accumulation in early AD, reducing reliance on tau PET scans and broadening its clinical application.

  3. Plasma pTau217 predicts continuous brain amyloid levels in preclinical and early Alzheimer's disease

    ✓ Peer-reviewed alzhub usefulness score 55 out of 100. Alzheimer's & dementia : the journal of the Alzheimer's Association 2024-06-28 Biomarkers

    Models integrating pTau217R outperformed Aβ42/Aβ40 alone, predicting amyloid levels up to 89.1 CL.

  4. Clinical evaluation of a novel plasma pTau217 electrochemiluminescence immunoassay in Alzheimer's disease

    ✓ Peer-reviewed alzhub usefulness score 57 out of 100. Scientific reports 2024-01-05 Biomarkers

    A growing literature suggests that plasma levels of tau phosphorylated at amino acid 217 (pTau217) performs similarly to cerebrospinal fluid (CSF) biomarkers and PET imaging to detect amyloid pathology and to provide diagnostic and prognostic information in Alzheimer's disease (AD), but a significant limiting factor thus far has been a lack of widely available immunoassays.

All topic tags with their study counts